March 17, 2022

Web Announcement 2739

Emergency Use Authorization Revoked for Monoclonal Antibody Injection and Infusion Codes

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) revocation for the monoclonal antibody procedure codes listed below due to the high frequency of the Omicron variant. The following injection and infusion/administration codes are not authorized effective with dates of service on or after January 25, 2022, and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.

Procedure Code	Description
Q0240	Regeneron Injection, casirivimab and imdevimab, 600mg
M0240	Regeneron Intravenous infusion or subcutaneous injection, casirivam and imevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
Q0243	Regeneron Injection, casirivimab and imdevimab, 2400 mg
M0243	Regeneron Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
Q0244	Regeneron Injection, casirivimab and imdevimab, 1200 mg
M0244	Regeneron Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
Q0245	Eli Lilly Injection, bamlanivimab and etesevimab, 2100 mg
M0245	Eli Lilly intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
M0246	Eli Lilly Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

The following provider types (PTs) are impacted:

Provider Type	Description
12	Hospital, Outpatient
20	Physician, M.D., Osteopath, D.O.
24	Advanced Practice Registered Nurse (APRN)
77	Physician's Assistant

Claims for the above codes should be denying with error code 3340 (Service not covered by Nevada Medicaid). If any claims for monoclonal antibody codes have been paid as of dates of service on or after January 25, 2022, they may be

reprocessed automatically to recoup the payments. A future web announcement will notify providers if claims are re-processed.

When claims are reprocessed, please be aware that all system and clinical claim editor edits are applicable. As a result, there may be no additional payment, and other claim denials may be received. Providers have the right to appeal denied claims, including those denied upon reprocessing. Please refer to Medicaid Services Manual Chapter 100 and the Billing Manual for information concerning the claim appeal process and time frames.